Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem) Versus a Combination Therapy With Moxifloxacin (Avalox) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shock.

Trial Profile

Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem) Versus a Combination Therapy With Moxifloxacin (Avalox) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shock.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Meropenem (Primary) ; Moxifloxacin (Primary)
  • Indications Sepsis; Septic shock
  • Focus Therapeutic Use
  • Acronyms MaxSep
  • Most Recent Events

    • 13 Jun 2012 Results published in JAMA: the Journal of the American Medical Association.
    • 13 Jun 2012 Primary endpoint 'Assessment-scale-scores' has not been met.
    • 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top